(Q37955284)

25 August 2017

Telmisartan: just an antihypertensive agent? A literature review (English)

1 reference

25 August 2017

1 reference

Maurizio Destro

1

1 reference

25 August 2017

Francesca Cagnoni

2

1 reference

25 August 2017

Giuseppina Patrizia Dognini

3

1 reference

25 August 2017

Vincenzo Galimberti

4

1 reference

25 August 2017

Carlo Taietti

5

1 reference

25 August 2017

Chiara Cavalleri

6

1 reference

25 August 2017

Emilio Galli

7

1 reference

25 August 2017

language of work or name

English

0 references

publication date

1 December 2011

1 reference

Expert Opinion on Pharmacotherapy

25 August 2017

1 reference

25 August 2017

12

1 reference

25 August 2017

17

1 reference

25 August 2017

2719-2735

1 reference

Cardiovascular disease risk factors: epidemiology and risk assessment.

25 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Telmisartan, ramipril, or both in patients at high risk for vascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Molecular mechanisms of human hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

A comparison of the properties and enzymatic activities of three angiotensin processing enzymes: angiotensin converting enzyme, prolyl endopeptidase and neutral endopeptidase 24.11.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Isolation and identification of proangiotensin-12, a possible component of the renin-angiotensin system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Localization of the novel angiotensin peptide, angiotensin-(1-12), in heart and kidney of hypertensive and normotensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Differential regulation of angiotensin-(1-12) in plasma and cardiac tissue in response to bilateral nephrectomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Cardiac chymase converts rat proAngiotensin-12 (PA12) to angiotensin II: effects of PA12 upon cardiac haemodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Aliskiren and valsartan in stage 2 hypertension: subgroup analysis of a randomized, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Telmisartan: a review of its pharmacodynamic and pharmacokinetic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

New standards in hypertension and cardiovascular risk management: focus on telmisartan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Telmisartan: a review of its use in cardiovascular disease prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Telmisartan: a review of its use in the management of hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Angiotensin II receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Effect of telmisartan on renal outcomes: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Telmisartan to prevent recurrent stroke and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Effects of telmisartan 80 mg and valsartan 160 mg on ambulatory blood pressure in patients with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Efficacy and duration of action of the four selective angiotensin II subtype 1 receptor blockers, losartan, candesartan, valsartan and telmisartan, in patients with essential hypertension determined by home blood pressure measurements.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

A systematic review and meta-analysis of telmisartan versus valsartan in the management of essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

A multicenter, 14-week study of telmisartan and ramipril in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Sustained antihypertensive activity of telmisartan compared with valsartan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

The prospective, randomized investigation of the safety and efficacy of telmisartan versus ramipril using ambulatory blood pressure monitoring (PRISMA I).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Comparison of telmisartan versus losartan: meta-analysis of titration-to-response studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Effectiveness of hydrochlorothiazide in combination with telmisartan and olmesartan in adults with moderate hypertension not controlled with monotherapy: a prospective, randomized, open-label, blinded end point (PROBE), parallel-arm study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Comparison of trough effect of telmisartan vs perindopril using self blood pressure measurement: EVERESTE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Blood pressure- and pulse pressure-lowering effects, trough:peak ratio and smoothness index of telmisartan compared with lisinopril.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Comparison of telmisartan with lisinopril in patients with mild-to-moderate hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Comparison of 26-week efficacy and tolerability of telmisartan and atenolol, in combination with hydrochlorothiazide as required, in the treatment of mild to moderate hypertension: a randomized, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Three-dimensional echocardiographic and magnetic resonance assessment of the effect of telmisartan compared with carvedilol on left ventricular mass a multicenter, randomized, longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension: a 12-month, randomized,

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Effects of telmisartan and amlodipine in combination on ambulatory blood pressure in stages 1-2 hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Telmisartan/amlodipine: single-pill combination in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Asse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

The effect of telmisartan on endothelial function and arterial stiffness in patients with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Effects of telmisartan added to Angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Angiotensin II as a mediator of tubulointerstitial injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Preventing renal complications in diabetic patients: the Diabetics Exposed to Telmisartan And enalaprIL (DETAIL) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Telmisartan improves endothelial function in patients with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Effect of telmisartan on forearm postischemic hyperemia and serum asymmetric dimethylarginine levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Telmisartan increases the permeability of endothelial cells through zonula occludens-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Heart Disease and Stroke Statistics--2010 Update: A Report From the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Aging and heart failure: changing demographics and implications for therapy in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Telmisartan attenuates fatty-acid-induced oxidative stress and NAD(P)H oxidase activity in pancreatic beta-cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Efficacy and safety of telmisartan, a selective AT1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension. TEES Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Effects of telmisartan on arterial stiffness in Type 2 diabetes patients with essential hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

The treatment of hypertension with telmisartan in the sphere of circadian rhythm in metabolic syndrome in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Assessment and management of hypertension in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Trends of elevated blood pressure among children and adolescents: data from the National Health and Nutrition Examination Survey1988-2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Safety, efficacy, and pharmacokinetics of telmisartan in pediatric patients with hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

A pooled analysis of seven randomized crossover studies of the palatability of cefdinir oral suspension versus amoxicillin/clavulanate potassium, cefprozil, azithromycin, and amoxicillin in children aged 4 to 8 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

"Why do they do that?" The compliance conundrum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Palatability of angiotensin II antagonists among nephropathic children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

PPAR(gamma) and glucose homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Vascular protective effects by activation of nuclear receptor PPARgamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Effect of telmisartan on nitric oxide--asymmetrical dimethylarginine system: role of angiotensin II type 1 receptor gamma and peroxisome proliferator activated receptor gamma signaling during endothelial aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Angiotensin II receptor blockers and cardiovascular protection: focus on left ventricular hypertrophy regression and atrial fibrillation prevention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Regression of left ventricular hypertrophy and improvement of diastolic function in hypertensive patients treated with telmisartan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Effects of telmisartan and losartan on insulin resistance in hypertensive patients with metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Comparison of the effects of ramipril versus telmisartan in reducing serum levels of high-sensitivity C-reactive protein and oxidized low-density lipoprotein cholesterol in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Improvement of endothelial function in patients with hypertension and type 2 diabetes after treatment with telmisartan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Effects of telmisartan on arterial stiffness assessed by the cardio-ankle vascular index in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Production and secretion of adiponectin from 3T3-L1 adipocytes: comparison of antihypertensive drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

Effects of ARB or ACE-inhibitor administration on plasma levels of aldosterone and adiponectin in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.632367

10.1517/14656566.2011.632367

21 January 2018

Identifiers

DOI

1 reference

25 August 2017

1 reference